Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Pei‐Chih Lee(The University of Texas MD Anderson Cancer Center), Mien‐Chie Hung(Precision Therapeutics (United States)), Yueh‐Fu Fang(The University of Texas MD Anderson Cancer Center), Shu‐Fen Chiang(China Medical University), Xuan Hong(Harbin Medical University), Wenhao Yang(Fujian Agriculture and Forestry University), Zhengyu Zha(Sichuan University), Chih‐Yen Tu(National Chung Hsing University), Jennifer L. Hsu(The University of Texas MD Anderson Cancer Center), Kwok‐Kin Wong(NYU Langone Health), Chun‐Te Chen(Sinotech Genomics (China)), Bingliang Fang(The University of Texas MD Anderson Cancer Center), Rong Deng(Sun Yat-sen University), Yi‐Hsin Elsa Hsu(The University of Texas MD Anderson Cancer Center), Wei‐Jan Wang(China Medical University), Chih‐Wei Wang(National Central University), Katsuya Nakai(The University of Texas MD Anderson Cancer Center), Hirohito Yamaguchi(China Medical University), Yan Wang(The University of Texas MD Anderson Cancer Center), Li Wang(The University of Texas MD Anderson Cancer Center), Ran Zhang(Jiangsu Cancer Hospital), Ting Chen(Tianjin University of Traditional Chinese Medicine), Lei Nie(Xinyang Normal University), Chia‐Hung Chen(The University of Texas MD Anderson Cancer Center), Jun Tang(Hubei University of Medicine), Junwei Hou(National Vaccine and Serum Institute), Han-Pin Kuo(Chang Gung University), Yongkun Wei(The University of Texas MD Anderson Cancer Center), Tai-Jan Chiu(The University of Texas MD Anderson Cancer Center), Tse-Ching Chen(Chang Gung University), Longfei Huo(The University of Texas MD Anderson Cancer Center), Weiya Xia(The University of Texas MD Anderson Cancer Center), Baozhen Ke(The University of Texas MD Anderson Cancer Center)
Cited by 71
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k